Vitamin D as an add-on Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis c
Status:
Unknown status
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Chronic hepatitis C is endemic in Egypt with a high prevalence of the resistant genotype 4.
Conventional standard of care treatment has modest response with only 50% sustained virologic
response. Recent reports have suggested an augmented response with the addition of vitamin D.
This is a prospective randomized trial to assess the effectiveness of adding vitamin D to
standard of care for chronic hepatitis C genotype 4.
Phase:
Phase 3
Details
Lead Sponsor:
Cairo University
Treatments:
Ergocalciferols Interferons Peginterferon alfa-2a Ribavirin Vitamin D Vitamins